Latest Story
Two Va. projects are finalists for $100M U.S. EDA grants
Proposals are two of 60
Two Virginia projects — one to make Central Virginia an advanced pharmaceutical manufacturing hub and one to support the transportation and logistics cluster in Southern and Southwest Virginia — are
More Stories
AMPAC expanding Petersburg operation, adding 156 jobs
Pharmaceutical manufacturer plans to invest $25 million
Published
AMPAC Fine Chemicals plans to grow its Petersburg manufacturing facility, investing $25 million and creating 156 jobs, Gov. Ralph Northam announced Tuesday. AMPAC manufactures active pharmaceutical ingredients (APIs) and is
Central Va. pharma hub strategic plan released
VCU announces strategy to drive business and job growth in region
Published
On Tuesday, the Virginia Commonwealth University College of Engineering announced its strategy to turn Central Virginia into an advanced pharmaceutical manufacturing, research and development hub. The strategic plan aims to
Advertisement
Phlow announces national coalition with children’s hospitals
Collaboration to address pediatric drug shortages
Published
Richmond-based Phlow Corp. announced Thursday the launch of a coalition that will help ensure that children’s hospitals across the country receive key medications. The Virginia Commonwealth University-affiliated Children’s Hospital of
$125M pharma manufacturing plant coming to Petersburg
Civica will manufacture COVID-19 medicines, partnering with Richmond's Phlow Corp.
Published
Utah-based pharmaceutical manufacturer Civica Inc. plans to invest $124.5 million to establish its North American manufacturing headquarters operation in Petersburg, creating 186 jobs and manufacturing injectable medicines for the treatment
Trump administration chooses RVA pharma startup for $354M COVID-19 contract
Phlow Corp. will create domestic supply chain for coronavirus drugs
Published
Richmond-based drug manufacturing company Phlow Corp., which incorporated this year, announced Tuesday that the Trump administration has awarded it a $354 million, four-year contract to manufacture in the U.S. generic